Financial Performance - Total revenue for the year ended December 31, 2025, was RMB 651.9 million, representing a year-on-year increase of 5.0% compared to RMB 620.7 million in 2024[3] - Gross profit for the same period was RMB 170.2 million, up 6.2% from RMB 160.2 million in 2024[3] - Adjusted net profit for the year was RMB 4.1 million, a significant improvement of 112.9% compared to an adjusted net loss of RMB 31.5 million in 2024[3] - Total revenue increased from approximately RMB 620.7 million in 2024 to approximately RMB 651.9 million in 2025, representing a growth of 5.0%[22] - Revenue from pharmaceutical health product sales rose from approximately RMB 426.5 million in 2024 to approximately RMB 442.9 million in 2025, marking a growth of 3.9%[22] - Revenue from digital healthcare solutions reached RMB 208.9 million, an increase of 7.6% from RMB 194.2 million in 2024[4] - The company reported a net loss attributable to shareholders of RMB 72,986 thousand for 2025, an improvement from a loss of RMB 107,687 thousand in 2024, representing a reduction of 32.2%[71] - The basic loss per share improved to RMB (0.24) in 2025 from RMB (0.37) in 2024, indicating a 35.1% decrease in loss per share[71] Revenue Breakdown - Revenue from pharmaceutical health products sales was RMB 442.9 million, reflecting a growth of 3.9% from RMB 426.5 million in 2024[4] - Revenue from digital healthcare solutions reached RMB 208.9 million, an increase of 7.6% from RMB 194.2 million in 2024[4] - Digital healthcare solutions revenue reached RMB 208.9 million, a year-on-year increase of 7.6%, accounting for 32.1% of total revenue in 2025, up from 31.3% in 2024[17] - Revenue from digital healthcare solutions increased by 7.6% from approximately RMB 194.2 million for the year ending December 31, 2024, to approximately RMB 208.9 million for the year ending December 31, 2025[23] Operational Metrics - The platform has expanded its service coverage to over 260 cities nationwide, connecting more than 45,125 healthcare institutions, a year-on-year growth of 1.18%[5] - The registered individual user base reached 61.1 million, marking a 13.12% increase year-on-year, with an average of 3.3 million monthly active users for the year[5] - The company has established partnerships with over 905,900 healthcare professionals, including approximately 47,800 registered doctors[5] - The total number of employees as of December 31, 2025, was 487, with 23.82% in sales and marketing, and 18.69% in R&D[44] Cost and Expenses - Cost of sales rose by 4.6% from approximately RMB 460.5 million for the year ending December 31, 2024, to approximately RMB 481.7 million for the year ending December 31, 2025[24] - Sales and marketing expenses decreased by 25.4% from approximately RMB 117.3 million for the year ending December 31, 2024, to approximately RMB 87.5 million for the year ending December 31, 2025[26] - Administrative expenses increased by 22.2% from approximately RMB 93.0 million for the year ending December 31, 2024, to approximately RMB 113.6 million for the year ending December 31, 2025[27] - Research and development expenses decreased by 30.8% from approximately RMB 50.5 million for the year ending December 31, 2024, to approximately RMB 35.0 million for the year ending December 31, 2025[28] Cash Flow and Financial Position - Cash and cash equivalents increased from approximately RMB 58.3 million as of December 31, 2024, to approximately RMB 398.8 million as of December 31, 2025[36] - The net cash used in operating activities for the year ended December 31, 2025, was RMB (114,438) thousand, compared to RMB (56,047) thousand in 2024, indicating a significant increase in cash outflow[37] - The company achieved a net increase in cash and cash equivalents of RMB 340,540 thousand for the year ended December 31, 2025, compared to RMB 711 thousand in 2024[37] - The debt-to-asset ratio improved to 69.2% as of December 31, 2025, down from 129.7% as of December 31, 2024, primarily due to increased capital raised post-IPO[42] - The total assets increased to RMB 759,927 thousand as of December 31, 2025, compared to RMB 297,773 thousand as of December 31, 2024[47] Strategic Initiatives - The digital healthcare solutions segment is identified as a strategic growth engine, driving future revenue growth and enhancing service capabilities[7] - The company aims to enhance operational efficiency through the integration of AI applications, upgrading its platform to improve patient experience and operational management for healthcare institutions[12] - The company plans to launch the AI hospital solution in 2025, integrating AI tools for patient management and operational efficiency[13] - The introduction of the Blue Spirit Control GPT product focuses on automatic risk management in healthcare, enhancing infection control and clinical decision-making[15] - A digital supply chain upgrade will be implemented, enhancing procurement decision-making and online sales services for corporate clients[19] - Continued investment in AI research and development will target high-frequency demand scenarios in the healthcare sector[21] - The company is committed to optimizing existing business structures and accelerating the deployment of AI technologies in healthcare services[20] - The digital hospital solutions will enhance resource allocation and response speed in healthcare institutions, improving overall service quality[14] Shareholder Information - The company did not declare any dividends for the years ended December 31, 2025, and 2024[73] - The company has no significant contingent liabilities or pledged assets as of December 31, 2025[40][41] Governance and Compliance - The company has adopted the corporate governance code as per the Hong Kong Stock Exchange listing rules, ensuring compliance since its listing date on September 17, 2025[78] - The audit committee has reviewed the financial reporting procedures and risk management practices of the group[89] - The external auditor has confirmed that the financial data in the preliminary performance announcement aligns with the draft consolidated financial statements[90] - No significant events have occurred after the reporting period and up to the date of this announcement[87]
健康１６０(02656) - 2025 - 年度业绩